Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA
Biogen pleased shareholders this week after it presented more data on its late-stage Alzheimer's drug, aducanumab. Shares of the biotech firm closed up 3.41% as analysts pointed to a lack of any new negatives compared with the aducanumab results released in October, which may increase the drug's odds of approval with the Food and Drug Administration.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063